Century Therapeutics (IPSC) Share-based Compensation (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Share-based Compensation data on file, last reported at $6.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 169.58% year-over-year to $6.5 million in Q1 2026; TTM through Mar 2026 was $6.5 million, a 45.07% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, down 46.09% from the prior year.
• Share-based Compensation for Q1 2026 stood at $6.5 million, up from $1.3 million in the prior quarter.
• Over the last five years, Share-based Compensation for IPSC reached as high as $6.5 million in Q1 2026 and fell as low as $1.3 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $3.0 million in 2022.
• Across the five-year window, Share-based Compensation soared 2405.26% in 2022 and tumbled 51.13% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $2.7 million in 2022, then surged by 30.38% to $3.6 million in 2023, then decreased by 25.32% to $2.7 million in 2024, then tumbled by 51.13% to $1.3 million in 2025, then soared by 403.08% to $6.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $6.5 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q2 2025.